Chronic spontaneous urticaria (CSU) formerly known as chronic idiopathic urticaria (CIU) is a severe and distressing skin condition that remains uncontrolled in approximately one half of patients...
Objective: To describe the baseline characteristics of the first 1539 German AWARE patients with H1-antihistamine-refractory CSU.
Objective: To describe disease burden, quality of life (QoL), and treatment patterns of patients with H1 antihistamine refractory CSU in Germany.
Omalizumab (a recombinant, humanized anti-immunoglobulin-E antibody) has been shown in three pivotal Phase III trials (ASTERIA I, II and GLACIAL) and real-world studies to be effective and well-tolerated for the treatment of chronic spontaneous urticaria (CSU), and is the only licensed third-line treatment for CSU.
Learn more about diagnosis and treatment of CSU
Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks.
How much do you know about chronic spontaneous urticaria (CSU)?
Novartis announced new baseline results from a real world study of 3,733 chronic urticaria (CU) patients showing many are not...
Containing relevant Learning Zones, guidelines, trials and news.
Video presentations of faculty experts speaking at the 23rd World Congress of Dermatology (WCD) 2015 have been added to...